A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

NCT ID: NCT01702571

Last Updated: 2022-04-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

2185 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-27

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior anti-HER2 and chemotherapy-based treatment. Participants in Cohort 1 will be drawn from the general participant population; Cohort 2 will include only Asian participants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Trastuzumab Emtansine (All Participants)

This cohort will enroll all participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.

Group Type EXPERIMENTAL

Trastuzumab Emtansine

Intervention Type DRUG

Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.

Trastuzumab Emtansine (Asian Participants)

This cohort will enroll Asian race participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.

Group Type EXPERIMENTAL

Trastuzumab Emtansine

Intervention Type DRUG

Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Trastuzumab Emtansine

Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RO5304020, T-DM1, Kadcyla

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HER2-positive disease determined locally
* Histologically or cytologically confirmed invasive breast cancer
* Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced or metastatic setting must include both chemotherapy, alone or in combination with another agent, and an anti-HER2 agent, alone or in combination with another agent
* Documented progression of incurable, unresectable, LABC, or mBC, defined by the investigator: progression must occur during or after most recent treatment for LABC/mBC or within 6 months of completing adjuvant therapy
* Measurable and/or non-measurable disease
* Left ventricular ejection fraction (LVEF) \>/=50% by either echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2
* Adequate organ function
* Use of highly effective contraception as defined by the protocol

Exclusion Criteria

* History of treatment with trastuzumab emtansine
* Prior enrollment into a clinical study containing trastuzumab emtansine regardless of having received trastuzumab emtansine or not
* Peripheral neuropathy of Grade \>/= 3 per National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v 4.0
* History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer
* History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to first study treatment except hormone therapy, which can be given up to 7 days prior to first study treatment; recovery of treatment-related toxicity consistent with other eligibility criteria
* History of exposure to cumulative doses of anthracyclines
* History of radiation therapy within 14 days of first study treatment. The participant must have recovered from any resulting acute toxicity (to Grade \</=1) prior to first study treatment.
* Metastatic central nervous system (CNS) disease only
* Brain metastases which are symptomatic
* History of a decrease in LVEF to less than (\<) 40% or symptomatic congestive heart failure (CHF) with previous trastuzumab treatment
* History of symptomatic CHF (New York Heart Association \[NYHA\] Classes II-IV) or serious cardiac arrhythmia requiring treatment
* History of myocardial infarction or unstable angina within 6 months of first study treatment
* Current dyspnea at rest due to complications of advanced malignancy or requirement for continuous oxygen therapy
* Current severe, uncontrolled systemic disease (clinically significant cardiovascular, pulmonary, or metabolic disease)
* Pregnancy or lactation
* Currently known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
* History of intolerance (such as Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins or any component of the product
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CEMIC

Buenos Aires, , Argentina

Site Status

Centro Oncologico Riojano Integral (CORI)

La Rioja, , Argentina

Site Status

Hospital Privado De Comunidad; General Practice

Mar del Plata, , Argentina

Site Status

Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research

North Sydney, New South Wales, Australia

Site Status

Calvary Mater Newcastle; Medical Oncology

Waratah, New South Wales, Australia

Site Status

Westmead Hospital; Medical Oncology and Pallative Care

Westmead, New South Wales, Australia

Site Status

Haematology & Oncology Clinics of Australia Research Centre

South Brisbane, Queensland, Australia

Site Status

Ashford Cancer Center Research

Kurralta Park, South Australia, Australia

Site Status

Peter MacCallum Cancer Centre; Medical Oncology

Melbourne, Victoria, Australia

Site Status

Sunshine Hospital; Oncology Research

St Albans, Victoria, Australia

Site Status

Fiona Stanley Hospital

Murdoch, Western Australia, Australia

Site Status

Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.

Salzburg, , Austria

Site Status

Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie

Vienna, , Austria

Site Status

Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie

Vienna, , Austria

Site Status

Institut Jules Bordet

Anderlecht, , Belgium

Site Status

UZ Brussel

Brussels, , Belgium

Site Status

Cliniques Universitaires St-Luc

Brussels, , Belgium

Site Status

GHdC Site Notre Dame

Charleroi, , Belgium

Site Status

UZ Antwerpen

Edegem, , Belgium

Site Status

UZ Gent

Ghent, , Belgium

Site Status

UZ Leuven Gasthuisberg

Leuven, , Belgium

Site Status

CHU Sart-Tilman

Liège, , Belgium

Site Status

Clinique Ste-Elisabeth

Namur, , Belgium

Site Status

Sint Augustinus Wilrijk, Apotheek

Wilrijk, , Belgium

Site Status

*X*Instituto Nacional do Cancer - INCA

Rio de Janeiro, Rio de Janeiro, Brazil

Site Status

Hospital Sao Lucas - PUCRS

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Centro de Pesquisas Oncologicas - CEPON

Florianópolis, Santa Catarina, Brazil

Site Status

Hospital Sirio Libanes; Centro de Oncologia

São Paulo, São Paulo, Brazil

Site Status

Hospital Sao Jose

São Paulo, São Paulo, Brazil

Site Status

MHAT Serdika; Department of medical oncology

Sofia, , Bulgaria

Site Status

SHATO - Sofia

Sofia, , Bulgaria

Site Status

SHATOD - Sofia

Sofia, , Bulgaria

Site Status

District Oncology Dispensary Wit Stationary

Varna, , Bulgaria

Site Status

BC Cancer - Surrey

Surrey, British Columbia, Canada

Site Status

British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre

Vancouver, British Columbia, Canada

Site Status

Dr. H. Bliss Murphy Cancer Centre; Oncology

St. John's, Newfoundland and Labrador, Canada

Site Status

Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials

Barrie, Ontario, Canada

Site Status

London Regional Cancer Centre

London, Ontario, Canada

Site Status

Southlake Regional Health Center; Community Care Clinic / Oncology

Newmarket, Ontario, Canada

Site Status

St. Michael'S Hospital

Toronto, Ontario, Canada

Site Status

Hopital Maisonneuve- Rosemont; Oncology

Montreal, Quebec, Canada

Site Status

Mcgill University - Royal Victoria Hospital; Oncology

Montreal, Quebec, Canada

Site Status

Cancer Hospital Chinese Academy of Medical Sciences.

Beijing, , China

Site Status

Beijing Cancer Hospital

Beijing, , China

Site Status

Chinese PLA General Hospital

Beijing, , China

Site Status

Sun Yat-sen Memorial Hospital

Guangzhou, , China

Site Status

Sun Yet-sen University Cancer Center

Guangzhou, , China

Site Status

Harbin Medical University Cancer Hospital

Harbin, , China

Site Status

Jiangsu Cancer Hospital

Nanjing, , China

Site Status

Fudan University Shanghai Cancer Center

Shanghai, , China

Site Status

Tianjin Cancer Hospital

Tianjin, , China

Site Status

Zhejiang Cancer Hospital

Zhejiang, , China

Site Status

Clinical Hospital Centre Zagreb

Zagreb, , Croatia

Site Status

Aalborg Universitetshospital, Klinik Kirurgi-Kræft, Onkologisk afd.

Aalborg, , Denmark

Site Status

Herlev Hospital; Afdeling for Kræftbehandling

Herlev, , Denmark

Site Status

Nordsjællands Hospital, Hillerød, Onkologisk Afdeling

Hillerød, , Denmark

Site Status

Rigshospitalet; Onkologisk Klinik

København Ø, , Denmark

Site Status

Odense Universitetshospital, Onkologisk Afdeling R

Odense C, , Denmark

Site Status

Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium

Roskilde, , Denmark

Site Status

Vejle Sygehus; Onkologisk Afdeling

Vejle, , Denmark

Site Status

Hospital Metropolitano de Santiago

Santiago de los Caballeros, , Dominican Republic

Site Status

Clinica Alcivar, torre 1;Private office

Guayaquil, , Ecuador

Site Status

Hospital Solca Portoviejo; Oncologia

Portoviejo, , Ecuador

Site Status

North Estonia Medical Centre Foundation; Oncology Center

Tallinn, , Estonia

Site Status

Helsingin yliopistollinen keskussairaala

Helsinki, , Finland

Site Status

KYS Sadesairaala; Syopatautien poliklinikka

Kuopio, , Finland

Site Status

Tampere University Hospital; Dept of Oncology

Tampere, , Finland

Site Status

Turku Uni Central Hospital; Oncology Clinics

Turku, , Finland

Site Status

Clinique De L Europe; Radiotherapie Chimiotherapie

Amiens, , France

Site Status

ICO Paul Papin; Oncologie Medicale.

Angers, , France

Site Status

Institut Sainte Catherine

Avignon, , France

Site Status

Hopital Jean Minjoz - CHU de Besançon

Besançon, , France

Site Status

Clinique Tivoli; Chimiotherapie Radiotherapie

Bordeaux, , France

Site Status

Institut Bergonie; Oncologie

Bordeaux, , France

Site Status

Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie

Bordeaux, , France

Site Status

Cli De La Porte De Saint Cloud; Hop De Jour De Chimiotherapie

Boulogne-Billancourt, , France

Site Status

Hopital Morvan; Oncologie - Radiotherapie

Brest, , France

Site Status

Centre Francois Baclesse; Radiotherapie

Caen, , France

Site Status

Centre Jean Perrin; Oncologie

Clermont-Ferrand, , France

Site Status

Centre Georges Francois Leclerc; Oncologie 3

Dijon, , France

Site Status

Chu Grenoble - Hopital Albert Michallon; Departement de Cancero-Hematologie

Grenoble, , France

Site Status

Centre Hartmann

Levallois-Perret, , France

Site Status

Centre Oscar Lambret; Senologie

Lille, , France

Site Status

Clinique Chenieux; Oncology

Limoges, , France

Site Status

Ch Bretagne Sud Site Scorff; Oncologie Medicale

Lorient, , France

Site Status

Centre Leon Berard

Lyon, , France

Site Status

Institut Paoli Calmettes; Oncologie Medicale

Marseille, , France

Site Status

Hopital Layne; Medecine Ambulatoire

Mont-de-Marsan, , France

Site Status

Centre Val Aurelle Paul Lamarque; Recherche Clinique

Montpellier, , France

Site Status

Centre Antoine Lacassagne; Hopital De Jour A2

Nice, , France

Site Status

Institut Curie; Oncologie Medicale

Paris, , France

Site Status

HOPITAL TENON; Cancerologie Medicale

Paris, , France

Site Status

Centre Catalan D' Oncologie

Perpignan, , France

Site Status

Polyclinique Francheville; Med Chimiotherapie Radiotherapie

Périgueux, , France

Site Status

Clinique Armoricaine Radiologie; Hopital de Jour

Plérin, , France

Site Status

Pole Regional De Cancerologie

Poitiers, , France

Site Status

Institut Jean Godinot; Oncologie Medicale

Reims, , France

Site Status

Polyclinique De Courlancy; Centre Radiotherapie Oncologie

Reims, , France

Site Status

Centre Eugene Marquis; Unite Huguenin

Rennes, , France

Site Status

Centre Henri Becquerel; Oncologie Medicale

Rouen, , France

Site Status

Centre Rene Huguenin; CONSULT SPECIALISEES

Saint-Cloud, , France

Site Status

Ico Rene Gauducheau; Oncologie

Saint-Herblain, , France

Site Status

Centre Paul Strauss; Oncologie Medicale

Strasbourg, , France

Site Status

Institut Claudius Regaud; Departement Oncologie Medicale

Toulouse, , France

Site Status

Clinique Pasteur; Oncologie Medicale

Toulouse, , France

Site Status

Centre Henry S Kaplan - CHU Bretonneau ; service oncologie

Tours, , France

Site Status

Centre Alexis Vautrin; Oncologie Medicale

Vandœuvre-lès-Nancy, , France

Site Status

Institut Gustave Roussy; Pathologie Mammaire

Villejuif, , France

Site Status

Hämatologisch-onkologische Praxis Dr. med. - Heinrich, - Bangerter

Augsburg, , Germany

Site Status

Praxis Dres. Schilling & Till

Berlin, , Germany

Site Status

Schwerpunktpraxis Onkologie/Hämatologie Dr. Dirk Pott, Dr. Christian Tirier und Carla Verena u.w.

Bottrop, , Germany

Site Status

Onkozentrum Dres. Göhler

Dresden, , Germany

Site Status

Dres. Joerg Weniger, Annette Bittrich und Berit Schuetze

Erfurt, , Germany

Site Status

Universitätsklinikum Erlangen; Frauenklinik

Erlangen, , Germany

Site Status

OncoResearch Lerchenfeld GmbH

Hamburg, , Germany

Site Status

HOPA MVZ GmbH

Hamburg, , Germany

Site Status

Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie

Hanover, , Germany

Site Status

Institut für Versorgungsforschung in der Onkologie GbR Koblenz

Koblenz, , Germany

Site Status

Klinikum Leverkusen; Med. Klinik III / Onkologie

Leverkusen, , Germany

Site Status

Klinikum der Universität München; Campus Großhadern; Klinik und Poliklinik für Frauenheilkunde

München, , Germany

Site Status

Universitätsklinikum Münster; Klinik für Frauenheilkunde und Geburtshilfe

Münster, , Germany

Site Status

Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe

Offenbach, , Germany

Site Status

Praxis für Hämatologie und Onkologie

Porta Westfalica, , Germany

Site Status

Universitaetsfrauenklinik; Und Poliklinik Am Klinikum

Rostock, , Germany

Site Status

Universitätsklinik Tübingen; Frauenklinik

Tübingen, , Germany

Site Status

HELIOS Dr. Horst Schmidt Kliniken Wiesbaden; Klinik für Gynäkologie und gynäkologische Onkologie

Wiesbaden, , Germany

Site Status

Hämatologisch-Onkologische Schwerpunktpraxis Dres. Schlag & Schöttker

Würzburg, , Germany

Site Status

University General Hospital of Heraklion

Crete, , Greece

Site Status

Uni Hospital of Ioannina; Oncology Dept.

Ioannina, , Greece

Site Status

University Hospital of Patras Medical Oncology

Pátrai, , Greece

Site Status

Papageorgiou General Hospital; Medical Oncology

Thessaloniki, , Greece

Site Status

Centro Oncológico Sixtino / Centro Oncológico SA

Guatemala City, , Guatemala

Site Status

Princess Margaret Hospital; Oncology

Hong Kong, , Hong Kong

Site Status

Prince of Wales Hosp; Dept. Of Clinical Onc

Shatin, , Hong Kong

Site Status

Ogyi, Orszagos Gyogyszereszeti Intezet

Budapest, , Hungary

Site Status

Szent Imre Hospital; Dept. of Oncology

Budapest, , Hungary

Site Status

Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly

Budapest, , Hungary

Site Status

Magyar Honvedseg Egeszsegugyi Kozpont; Fázis I-es Klinikai Farmakológiai Vizsgálóhely

Budapest, , Hungary

Site Status

Kaposi Mor County Hospital; Dept. of Oncology

Kaposvár, , Hungary

Site Status

Landspitali University Hospital, Department of Medical Oncology

Reykjavik, , Iceland

Site Status

Cipto Mangunkusumo General Hospital; Hematology & Oncology

Jakarta, , Indonesia

Site Status

Dharmais National Cancer Center

Jakarta, , Indonesia

Site Status

MRCCC Siloam Semanggi Hospital

Jakarta, , Indonesia

Site Status

Cork Uni Hospital; Oncology Dept

Cork, , Ireland

Site Status

St Vincent'S Uni Hospital; Medical Oncology

Dublin, , Ireland

Site Status

Mater Misericordiae Uni Hospital; Oncology

Dublin, , Ireland

Site Status

University Hospital Limerick - Oncology

Limerick, , Ireland

Site Status

Ospedale Antonio Perrino; Oncologia Medica

Brindisi, Apulia, Italy

Site Status

Ospedale Vito Fazzi; Div. Oncoematologia

Lecce, Apulia, Italy

Site Status

Azienda Ospedaliera San Giuseppe Moscati

Avellino, Campania, Italy

Site Status

Istituto Nazionale Tumori Fondazione G. Pascale

Napoli, Campania, Italy

Site Status

Università degli Studi Federico II; Clinica di Oncologia Medica

Napoli, Campania, Italy

Site Status

Ospedale Bellaria; U.O. Oncologia Medica

Bologna, Emilia-Romagna, Italy

Site Status

A.O.U. Policlinico di Modena

Modena, Emilia-Romagna, Italy

Site Status

Az. Osp. Ospedale Civile; U.O. Di Oncologia Medica Ed Ematologia

Piacenza, Emilia-Romagna, Italy

Site Status

RCCS - Centro di Riferimento; Oncologia Medica B

Aviano (PN), Friuli Venezia Giulia, Italy

Site Status

Divisione Onc Med dell'Azienda

Udine, Friuli Venezia Giulia, Italy

Site Status

Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche

Rome, Lazio, Italy

Site Status

Ospedale S.S. Trinità Nuovo; Divisione Oncologia

Sora, Lazio, Italy

Site Status

IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A

Genoa, Liguria, Italy

Site Status

ASST DI CREMONA; Unità di Patologia Mammaria Senologia e Breast Unit

Cremona, Lombardy, Italy

Site Status

ASST DI LECCO; Oncologia Medica

Lecco, Lombardy, Italy

Site Status

Ospedale San Raffaele; Medical Oncology

Milan, Lombardy, Italy

Site Status

Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1

Milan, Lombardy, Italy

Site Status

Istituto Europeo Di Oncologia

Milan, Lombardy, Italy

Site Status

Fondazione Salvatore Maugeri; Divisione Di Oncologia Medica

Pavia, Lombardy, Italy

Site Status

Casa di Cura Multimedica S.p.A.; Dipartimento Oncologico

Sesto San Giovanni (MI), Lombardy, Italy

Site Status

Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico

Candiolo, Piedmont, Italy

Site Status

Ospedale Maggiore Della Carita; Oncologia Medica

Novara, Piedmont, Italy

Site Status

A.O. Città della Salute e della Scienza - Presidio Molinette; divisione oncologia medica

Turin, Piedmont, Italy

Site Status

Az Ospedaliera Nuovo Garibaldi Quartiere Nesima; Oncologia Medica

Catania, Sicily, Italy

Site Status

A.O.U Careggi

Florence, Tuscany, Italy

Site Status

Azienda usl 5 Di Pisa-Ospedale Di Pontedera;U.O. Oncologia

Pontedera, Tuscany, Italy

Site Status

Ospedale Misericordia E Dolce; Oncologia Medica

Prato, Tuscany, Italy

Site Status

Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica

Perugia, Umbria, Italy

Site Status

Ospedale Civile; Oncologia Medica

Camposampiero, Veneto, Italy

Site Status

Ospedale Busonera; Oncologia Medica

Padua, Veneto, Italy

Site Status

A.O.U.I. VERONA-OSPEDALE BORGO TRENTO; ONCOLODIA MEDICA-d.O.

Verona, Veneto, Italy

Site Status

CHL Hopital Municipal; Oncology

Luxembourg, , Luxembourg

Site Status

Hospital General de México

Mexico City, Mexico CITY (federal District), Mexico

Site Status

Medica Sur Centro Oncologico Integral

D.F., , Mexico

Site Status

Hospital Hmg Coyoacan

DF, , Mexico

Site Status

CENTRO MÉDICO NACIONAL SIGLO XXI; Hospital de Especialidades Oncología

Mexico City, , Mexico

Site Status

Inst. Nacional de Cancerologia; Investigacion Clinica

Mexico City, , Mexico

Site Status

Instituto Nacional de Ciencias Médicas Y de La Nutricion Zubirán

Mexico City, , Mexico

Site Status

Antoni Van Leeuwenhoek Ziekenhuis; Inwendige Geneeskunde

Amsterdam, , Netherlands

Site Status

Amphia Ziekenhuis

Breda, , Netherlands

Site Status

Deventer Ziekenhuis; Interne Geneeskunde

Deventer, , Netherlands

Site Status

Ziekenhuisgroep Twente, Hengelo

Hengelo, , Netherlands

Site Status

Spaarne Ziekenhuis; Inwendige Geneeskunde

Hoofddorp, , Netherlands

Site Status

Medisch Centrum Leeuwarden; Interne

Leeuwarden, , Netherlands

Site Status

Orbis Medisch Centrum; Inwendige Geneeskunde

Sittard-Geleen, , Netherlands

Site Status

MC Haaglanden; Oncologie

The Hague, , Netherlands

Site Status

Twee Steden Ziekenhuis - Locatie Tilburg; Interne Geneesekunde

Tilburg, , Netherlands

Site Status

Oslo Universitetssykehus HF; Ullevål sykehus

Oslo, , Norway

Site Status

Centro Hemato Oncologico Panama

Panama City, , Panama

Site Status

Centro Oncologico America

Panama City, , Panama

Site Status

Instituto;Oncologico Miraflores

Lima, , Peru

Site Status

Clinica de Especialidades Medicas

Lima, , Peru

Site Status

Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej

Bialystok, , Poland

Site Status

Szpital Specjalistyczny POO im. ks. B.Markiewicza; Dzienny Oddz Chemioter i Hematologii Onkol

Brzozów, , Poland

Site Status

Świętokrzyskie Centrum Onkologii; Dział Chemioterapii

Kielce, , Poland

Site Status

Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii

Krakow, , Poland

Site Status

Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii

Otwock, , Poland

Site Status

Wojewódzki Szpital Specjalistyczny Nr 3

Rybnik, , Poland

Site Status

IPO de Lisboa; Servico de Oncologia Medica

Lisbon, , Portugal

Site Status

Hospital da Luz; Departamento de Oncologia Medica

Lisbon, , Portugal

Site Status

IPO do Porto; Servico de Oncologia Medica

Porto, , Portugal

Site Status

Narodny Onkologicky Ustav; Oddelenie klinickej onkologie A

Bratislava, , Slovakia

Site Status

Fakultna nemocnica Trencín; Onkologicke odd.

Trenčín, , Slovakia

Site Status

Institute of Oncology Ljubljana

Ljubljana, , Slovenia

Site Status

Kyungpook National University Medical Center

Daegu, , South Korea

Site Status

Gachon Medical School Gil Medical Center; Medical Oncology

Incheon, , South Korea

Site Status

Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology

Seoul, , South Korea

Site Status

Yonsei University Severance Hospital; Medical Oncology

Seoul, , South Korea

Site Status

Korea University Anam Hospital; Oncology Haemotology

Seoul, , South Korea

Site Status

Hospital General Universitario de Elche; Servicio de Oncologia

Elche, Alicante, Spain

Site Status

Hospital General de Elda; Servicio de Oncologia

Elda, Alicante, Spain

Site Status

Hospital Universitario Son Espases

Palma de Mallorca, Balearic Islands, Spain

Site Status

Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia

Badalona, Barcelona, Spain

Site Status

Corporacio Sanitaria Parc Tauli; Servicio de Oncologia

Sabadell, Barcelona, Spain

Site Status

Hospital de Jerez de la Frontera; Servicio de Oncologia

Jerez de la Frontera, Cadiz, Spain

Site Status

Hospital Universitario Reina Sofia; Servicio de Oncologia

Córdoba, Cordoba, Spain

Site Status

Hospital de Donostia; Servicio de Oncologia Medica

Donostia / San Sebastian, Guipuzcoa, Spain

Site Status

Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia

Las Palmas de Gran Canaria, LAS Palmas, Spain

Site Status

Hospital de Gran Canaria Dr. Negrin; Servicio de Oncologia

Las Palmas de Gran Canaria, LAS Palmas, Spain

Site Status

Hospital Severo Ochoa; Servicio de Oncologia

Leganés, Madrid, Spain

Site Status

Hospital Quiron de Madrid; Servicio de Oncologia

Pozuelo de Alarcón, Madrid, Spain

Site Status

Hospital Xeral Cíes; Servicio de Oncologia

Vigo, Pontevedra, Spain

Site Status

Hospital Univ. Central de Asturias; Servicio de Oncologia

Oviedo, Principality of Asturias, Spain

Site Status

Hospital Universitari Sant Joan de Reus; Servicio de Oncologia

Reus, Tarragona, Spain

Site Status

Hospital de Cruces; Servicio de Oncologia

Bilbao, Vizcaya, Spain

Site Status

Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología

A Coruña, , Spain

Site Status

Hospital General Univ. de Alicante; Servicio de Oncologia

Alicante, , Spain

Site Status

Hospital del Mar; Servicio de Oncologia

Barcelona, , Spain

Site Status

Hospital Quiron Barcelona; Servicio de Oncologia

Barcelona, , Spain

Site Status

Hospital San Pedro De Alcantara; Servicio de Oncologia

Cáceres, , Spain

Site Status

Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia

Girona, , Spain

Site Status

Hospital Universitario San Cecilio; Servicio de Oncologia

Granada, , Spain

Site Status

Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia

Jaén, , Spain

Site Status

Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia

Lleida, , Spain

Site Status

Hospital Ramon y Cajal; Servicio de Oncologia

Madrid, , Spain

Site Status

HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia

Madrid, , Spain

Site Status

Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia

Málaga, , Spain

Site Status

Complejo Hospitalario de Pontevedra; Servicio de Oncologia

Pontevedra, , Spain

Site Status

Instituto Valenciano Oncologia; Oncologia Medica

Valencia, , Spain

Site Status

Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia

Valencia, , Spain

Site Status

Hospital General Universitario de Valencia; Servicio de oncologia

Valencia, , Spain

Site Status

Hospital Universitario Miguel Servet; Servicio Oncologia

Zaragoza, , Spain

Site Status

Karolinska Hospital; Oncology - Radiumhemmet

Stockholm, , Sweden

Site Status

Norrlands universitetssjukhus; Onkologkliniken

Umeå, , Sweden

Site Status

National Cheng Kung Uni Hospital; Surgery

Tainan City, , Taiwan

Site Status

Chi-Mei Medical Centre; Hematology & Oncology

Tainan City, , Taiwan

Site Status

VETERANS GENERAL HOSPITAL; Department of General Surgery

Taipei, , Taiwan

Site Status

Department of Surgery, King Chulalongkorn Memorial Hospital

Bangkok, , Thailand

Site Status

Pramongkutklao Hospital; Medicine - Medical Oncology Unit

Bangkok, , Thailand

Site Status

Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial

Chiang Mai, , Thailand

Site Status

Gazi Uni Medical Faculty Hospital; Oncology Dept

Ankara, , Turkey (Türkiye)

Site Status

Gaziantep University Medical Faculty, Medical Oncology Department

Gaziantep, , Turkey (Türkiye)

Site Status

Bezmialem Vakif Univ Medical; Bezmialem Vakif Univ T

Istanbul, , Turkey (Türkiye)

Site Status

Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology

Istanbul, , Turkey (Türkiye)

Site Status

Istanbul Uni of Medicine Faculty; Oncology Dept

Istanbul, , Turkey (Türkiye)

Site Status

Kartal Dr Lutfi Kirdar Sehir Hastanesi; Medical Oncology Department

Istanbul, , Turkey (Türkiye)

Site Status

Marmara Uni Faculty of Medicine; Medical Oncology

Istanbul, , Turkey (Türkiye)

Site Status

Ege Uni Medical Faculty Hospital; Oncology Dept

Izmir, , Turkey (Türkiye)

Site Status

Dokuz Eylul Uni ; Medical Oncology

Izmir, , Turkey (Türkiye)

Site Status

Kocaeli University Faculty of Medicine; Medical oncology

İzmit, , Turkey (Türkiye)

Site Status

Tawam Hospital

Al Ain City, , United Arab Emirates

Site Status

Aberdeen Royal Infirmary

Aberdeen, , United Kingdom

Site Status

University Hospital Birmingham Queen Elizabeth Hospital

Birmingham, , United Kingdom

Site Status

Kent & Canterbury Hospital

Canterbury, , United Kingdom

Site Status

University Hospital coventry; Oncology Department

Coventry, , United Kingdom

Site Status

Eastborne District General Hospital

Eastbourne, , United Kingdom

Site Status

Western General Hospital; Clinical Oncology

Edinburgh, , United Kingdom

Site Status

St Margaret'S Hospital; Breast Unit

Epping, , United Kingdom

Site Status

Royal Devon & Exeter Hospital; Oncology Centre

Exeter, , United Kingdom

Site Status

Beatson West of Scotland Cancer Centre

Glasgow, , United Kingdom

Site Status

Diana Princess of Wales Hosp.

Grimsby, , United Kingdom

Site Status

Huddersfield Royal Infirmary

Huddersfield, , United Kingdom

Site Status

Castle Hill Hospital; The Queen's Centre for Oncology & Haematology

Hull, , United Kingdom

Site Status

Ipswich Hospital; Oncology Pharmacy

Ipswich, , United Kingdom

Site Status

Royal Lancaster Infirmary, Morecambe Bay Hospitals Nhs Trust

Lancaster, , United Kingdom

Site Status

Royal Free Hospital; Dept of Oncology

London, , United Kingdom

Site Status

Guys & St Thomas Hospital; Department of Oncology

London, , United Kingdom

Site Status

St George'S Hospital; Oncology Research Office /Oncology Opd

London, , United Kingdom

Site Status

Sarah Cannon Research Institute

London, , United Kingdom

Site Status

Maidstone & Tonbridge Wells Hospital; Kent Oncology Center

Maidstone, , United Kingdom

Site Status

Christie Hospital; Breast Cancer Research Office

Manchester, , United Kingdom

Site Status

Mount Vernon Hospital

Middlesex, , United Kingdom

Site Status

Plymouth Oncology Centre; Clinical Trials Unit

Plymouth, , United Kingdom

Site Status

Queen Alexandra Hospital, Portsmouth

Portsmouth, , United Kingdom

Site Status

Queen's Hospital; Oncology

Romford, , United Kingdom

Site Status

Weston Park Hospital; Cancer Clinical Trials Centre

Sheffield, , United Kingdom

Site Status

Royal Shrewsbury Hospital

Shrewsbury, , United Kingdom

Site Status

Singleton Hospital; Pharmacy

Swansea, , United Kingdom

Site Status

Yeovil District Hospital; Macmillan Cancer Unit

Yeovil, , United Kingdom

Site Status

York District Hospital

York, , United Kingdom

Site Status

Unidad de Mastologia y Atencion a la Mujer

Barcelona, , Venezuela

Site Status

Instituto Oncológico Luis Razetti

Caracas, , Venezuela

Site Status

Instituto de Oncologia y Hematologia UCV

Caracas, , Venezuela

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Argentina Australia Austria Belgium Brazil Bulgaria Canada China Croatia Denmark Dominican Republic Ecuador Estonia Finland France Germany Greece Guatemala Hong Kong Hungary Iceland Indonesia Ireland Italy Luxembourg Mexico Netherlands Norway Panama Peru Poland Portugal Slovakia Slovenia South Korea Spain Sweden Taiwan Thailand Turkey (Türkiye) United Arab Emirates United Kingdom Venezuela

References

Explore related publications, articles, or registry entries linked to this study.

Wuerstlein R, Ellis P, Montemurro F, Anton Torres A, Delaloge S, Zhang Q, Wang X, Wang S, Shao Z, Li H, Rachman A, Vongsaisuwon M, Liu H, Fear S, Pena-Murillo C, Barrios C. Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer. ESMO Open. 2022 Oct;7(5):100561. doi: 10.1016/j.esmoop.2022.100561. Epub 2022 Sep 7.

Reference Type DERIVED
PMID: 36084395 (View on PubMed)

Engebraaten O, Yau C, Berg K, Borgen E, Garred O, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer. Nat Commun. 2021 Nov 5;12(1):6427. doi: 10.1038/s41467-021-26018-z.

Reference Type DERIVED
PMID: 34741021 (View on PubMed)

Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, Hatschek T, Kelly CM, Pena-Murillo C, Yilmaz M, Donica M, Ellis P. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆. Ann Oncol. 2020 Oct;31(10):1350-1358. doi: 10.1016/j.annonc.2020.06.020. Epub 2020 Jul 5.

Reference Type DERIVED
PMID: 32634611 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-001628-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

MO28231

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.